SCHEMBL4990328

SCHEMBL4990328

O=C(O)CCc1cccc(N/C=C2\C(=O)Nc3ccccc32)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 3/20 0.50
KDR P35968 6/20 0.47
FGFR1 P11362 5/20 0.47
PDGFRB P09619 4/20 0.47
AURKA O14965 3/20 0.47
RET P07949 2/20 0.47
FLT3 P36888 2/20 0.47
ZAP70 P43403 2/20 0.47
MAP4K2 Q12851 2/20 0.47
STK3 Q13188 2/20 0.47
AURKB Q96GD4 2/20 0.47
SRC P12931 2/20 0.47
CDK1 P06493 2/20 0.47
GAK O14976 1/20 0.47
RPS6KA5 O75582 1/20 0.47
RPS6KA4 O75676 1/20 0.47
LATS1 O95835 1/20 0.47
CSNK2A2 P19784 1/20 0.47
MAP2K2 P36507 1/20 0.47
MAP2K1 Q02750 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4990335 1.00 FLT1 (0.50) FLT1KDRFGFR1PDGFRBAURKA
SCHEMBL6599412 0.90 ZAP70 (0.46) FLT1KDRFGFR1PDGFRBAURKA
SCHEMBL4993230 0.89 ALDH1A1 (0.49) FLT1KDRFLT3CDK1PLK4
SCHEMBL4993224 0.89 ALDH1A1 (0.49) FLT1KDRFLT3CDK1PLK4
SCHEMBL4991346 0.87 KDR (0.50) FLT1KDRFGFR1PDGFRBAURKA
SCHEMBL4991358 0.87 KDR (0.50) FLT1KDRFGFR1PDGFRBAURKA
SCHEMBL6599666 0.87 ALDH1A1 (0.47) KDRPDGFRBRETFLT3CDK1
SCHEMBL4993949 0.87 ZAP70 (0.51) KDRPDGFRBZAP70NTRK1RPS6KA3
SCHEMBL4989145 0.87 AURKA (0.48) FLT1KDRFGFR1PDGFRBAURKA
SCHEMBL4989152 0.87 AURKA (0.48) FLT1KDRFGFR1PDGFRBAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 US disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT1 591/4885KDR 256/4885FGFR1 346/4885
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT1 591/4885KDR 256/4885FGFR1 346/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT1 591/4885KDR 256/4885FGFR1 346/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT1 591/4885KDR 256/4885FGFR1 346/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT1 591/4885KDR 256/4885FGFR1 346/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT1 591/4885KDR 256/4885FGFR1 346/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT1 591/4885KDR 256/4885FGFR1 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.